Daily Judi: Friday, December 16, 2022
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
A joint statement published by the European Society of Cardiology, the World Heart Federation, the American Heart Association, and American College of Cardiology, argues for an evolution in randomized clinical trials, and "sustained efforts to increase the application of streamlined approaches." (Medical Xpress)
BioPharma Dive looks at Eli Lilly's projected growth, and its expectations in sales and drug development for 2023.
Heidi Ledford examines two recent studies on the success of chimeric antigen receptor (CAR)-T cancer therapies. (Nature)
Our Culture
“Dossiers and redaction are built within the Judi platform, which helps significantly with adjudication management—and the client collaborates on the process.”
–Jess, Program Manager
About Judi
Judi speeds and improves the world's clinical trial workflows. Our cloud-based platform has 120,000 users across 168 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.